{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T21:39:47Z","timestamp":1763156387477},"reference-count":5,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Case Reports"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.jaccas.2024.102414","type":"journal-article","created":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T18:37:43Z","timestamp":1723055863000},"page":"102414","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Drug Development for Transthyretin\u00a0Amyloidosis"],"prefix":"10.1016","volume":"29","author":[{"given":"Nowell M.","family":"Fine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald M.","family":"Witteles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.jaccas.2024.102414_bib1","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran\u00a0treatment in patients with transthyretin cardiac amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"N\u00a0Engl J Med"},{"journal-title":"Cardiovascular and Renal Drugs Advisory Committee (CRDAC) Meeting","article-title":"Supplemental new drug application (sNDA) 210922-S015 for Onpattro (patisiran) lipid complex injection for the proposed treatment of the cardiomyopathy of wild-type or hereditary transthyretin mediated amyloidosis in adults","year":"2023","key":"10.1016\/j.jaccas.2024.102414_bib2"},{"issue":"15","key":"10.1016\/j.jaccas.2024.102414_bib3","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","article-title":"Cost-effectiveness of tafamidis therapy for\u00a0transthyretin amyloid cardiomyopathy","volume":"141","author":"Kazi","year":"2020","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jaccas.2024.102414_bib4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/13506129.2023.2263620","article-title":"Heterogeneous worldwide access and pricing\u00a0of tafamidis","volume":"31","author":"Wardhere","year":"2024","journal-title":"Amyloid"},{"issue":"11","key":"10.1016\/j.jaccas.2024.102414_bib5","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N\u00a0Engl J Med"}],"container-title":["JACC: Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666084924002079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666084924002079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T21:20:54Z","timestamp":1726435254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666084924002079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":5,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2666084924002079"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccas.2024.102414","relation":{},"ISSN":["2666-0849"],"issn-type":[{"type":"print","value":"2666-0849"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug Development for Transthyretin\u00a0Amyloidosis","name":"articletitle","label":"Article Title"},{"value":"JACC: Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccas.2024.102414","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"102414"}}